Unknown PHASE2 INTERVENTIONAL NCT03412383

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Sponsor: Peking Union Medical College

Conditions Breast Cancer HER2 Gene Mutation

Interventions Pyrotinib

Updated 6 times since 2018 Last updated: Jan 28, 2018 Started: Feb 20, 2018 Primary completion: Jan 25, 2019 Completion: Jun 25, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and HER2 Gene Mutation and is currently ongoing. Peking Union Medical College leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Feb 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Feb 2020 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking Union Medical College

Data source: Peking Union Medical College

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China